The Governance Imperative
The EU AI Act classifies many pharmaceutical AI applications as high-risk, requiring conformity assessments, human oversight mechanisms, and transparency documentation. Swiss regulations add additional requirements through the nDSG and sector-specific Swissmedic guidance. Without proactive governance, pharmaceutical companies face regulatory penalties, reputational damage, and delayed AI deployments.
Framework Elements
- AI risk classification aligned with EU AI Act categories
- Model validation and performance monitoring standards adapted from GAMP 5
- Bias detection and mitigation protocols for clinical and commercial AI
- Explainability requirements calibrated to use case risk level
- Human oversight mechanisms for high-stakes decisions
- Incident response and model rollback procedures
Practical Implementation
Effective governance isn't bureaucracy — it's enablement. A well-designed framework accelerates AI deployment by providing clear guardrails that development teams can follow confidently, reducing the cycle of ad-hoc review and rework that plagues ungoverned AI programs.